The Nilotinib molecule of Swiss laboratory Novartis, marketed under the name Tasigna, allowed “a significant and encouraging improvement” in reducing toxic brain proteins. These proteins are associated with the progression of these neurodegenerative diseases, said the researchers at the Medical Center Georgetown University in Washington, whose clinical study involved twelve patients.

Their results were presented weekend at the annual conference of the American Society for Neuroscience in Chicago.

According to them, Tasigna improved cognition, motor skills and non-motor of patients with Parkinson’s and body disease Lewy, cognitive disorder characterized by abnormal deposits of protein forming inside nerve cells in the brain.

“To my knowledge this is the first time that a therapy appears to reverse to a greater or lesser degree depending on the progress of the disease, cognitive decline and functional ability of patients with these neurodegenerative disorders, “said Dr. Fernando Pagan, assistant professor of neurology at Georgetown University Hospital.

But, he added,” it is essential to conduct more extensive clinical study before . to determine the true impact of this drug ”

Researchers cited several examples to support their claims: a sick condemned to remain in a wheelchair because he could not get up, was able to walk again. Or three patients who could not speak were, after this treatment, hold normal conversations.

However, noted Dr. Pagan, there was no control group to compare patients with placebo or other treatments for Parkinson’s disease.

Researchers found that Tasigna had increased the production of dopamine, an important neurotransmitter that promotes communication between neurons.

According to them, stop Tasigna appeared to cause cognitive decline and motor skills and, despite the resumption of conventional therapies against Parkinson’s.